{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:29:42Z","timestamp":1762079382014,"version":"build-2065373602"},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,5,6]],"date-time":"2013-05-06T00:00:00Z","timestamp":1367798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2013,8]]},"abstract":"\n Aim<\/jats:title>\n \n The efficacy and safety of insulin degludec (\n IDeg<\/jats:styled-content>\n ), a new basal insulin with an ultra\u2010long duration of action, was compared to sitagliptin (Sita) in a 26\u2010week, open\u2010label trial.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Insulin\u2010na\u00efve subjects with type 2 diabetes [n\u2009=\u2009458, age: 56\u2009years, diabetes duration: 7.7\u2009years, glycosylated haemoglobin (\n HbA1c<\/jats:styled-content>\n ): 8.9% (74\u2009mmol\/mol)] were randomized (1\u2009:\u20091) to once\u2010daily\n IDeg<\/jats:styled-content>\n or Sita (100\u2009mg orally) as add\u2010on to stable treatment with 1 or 2 oral antidiabetic drugs (\n OADs<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Superiority of\n IDeg<\/jats:styled-content>\n to Sita in improving\n HbA1c<\/jats:styled-content>\n and fasting plasma glucose (\n FPG<\/jats:styled-content>\n ) was confirmed [estimated treatment difference (\n ETD<\/jats:styled-content>\n )\n IDeg<\/jats:styled-content>\n \u2013Sita for\n HbA1c<\/jats:styled-content>\n : \u22120.43%\u2010points [95% confidence interval (\n CI<\/jats:styled-content>\n ): \u22120.61; \u22120.24, p\u2009<\u20090.0001] and for\n FPG<\/jats:styled-content>\n : \u22122.17\u00a0mmol\/l (95%\n CI<\/jats:styled-content>\n : \u22122.59; \u22121.74, p\u2009<\u20090.0001)].\n HbA1c<\/jats:styled-content>\n \u2009<\u20097% (<53\u2009mmol\/mol) was achieved by 41% (\n IDeg<\/jats:styled-content>\n ) versus 28% (Sita) of patients, estimated odds ratio\n IDeg<\/jats:styled-content>\n \/Sita: 1.60 (95%\n CI<\/jats:styled-content>\n : 1.04; 2.47, p\u2009=\u20090.034). There was no statistically significant difference in the rate of nocturnal confirmed hypoglycaemia between\n IDeg<\/jats:styled-content>\n and Sita [0.52 vs. 0.30 episodes\/patient\u2010year, estimated rate ratio (\n ERR<\/jats:styled-content>\n ):\n IDeg<\/jats:styled-content>\n \/Sita: 1.93 (95%\n CI<\/jats:styled-content>\n : 0.90; 4.10, p\u2009=\u20090.09)]. Rates of overall confirmed hypoglycaemia were higher with\n IDeg<\/jats:styled-content>\n than with Sita [3.1 vs. 1.3 episodes\/patient\u2010year,\n ERR IDeg<\/jats:styled-content>\n \/Sita: 3.81 (95%\n CI<\/jats:styled-content>\n : 2.40; 6.05, p\u2009<\u20090.0001)].\n IDeg<\/jats:styled-content>\n was associated with a greater change in body weight than Sita [\n ETD IDeg<\/jats:styled-content>\n \u2013Sita: 2.75\u2009kg (95%\n CI<\/jats:styled-content>\n : 1.97; 3.54, p\u2009<\u20090.0001)]. The overall rates of adverse events were low and similar for both groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n In patients unable to achieve good glycaemic control on\n OAD<\/jats:styled-content>\n (s), treatment intensification with\n IDeg<\/jats:styled-content>\n offers an effective, well\u2010tolerated alternative to the addition of a second or third\n OAD<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12115","type":"journal-article","created":{"date-parts":[[2013,4,11]],"date-time":"2013-04-11T13:54:49Z","timestamp":1365688489000},"page":"760-766","source":"Crossref","is-referenced-by-count":32,"title":["Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents"],"prefix":"10.1111","volume":"15","author":[{"given":"A.","family":"Philis\u2010Tsimikas","sequence":"first","affiliation":[{"name":"Scripps Whittier Diabetes Institute San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Del Prato","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Section of Metabolic Diseases, University of Pisa Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Satman","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine Istanbul Medical Faculty, Istanbul University Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Iowa Diabetes & Endocrinology Research Center Des Moines IA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dharmalingam","sequence":"additional","affiliation":[{"name":"Bangalore Endocrinology & Diabetes Research Center Malleswaram Bangalore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. V.","family":"Skj\u00f8th","sequence":"additional","affiliation":[{"name":"Medical & Science, Novo Nordisk A\/S S\u00f8borg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Biostatistics, Novo Nordisk A\/S S\u00f8borg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Garber","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism Baylor College of Medicine Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,5,6]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_7_2_1","DOI":"10.1111\/j.1600-051X.1988.tb01003.x"},{"doi-asserted-by":"publisher","key":"e_1_2_7_3_1","DOI":"10.1056\/NEJM199309303291401"},{"doi-asserted-by":"publisher","key":"e_1_2_7_4_1","DOI":"10.1056\/NEJM199307293290502"},{"doi-asserted-by":"publisher","key":"e_1_2_7_5_1","DOI":"10.1056\/NEJMoa0806470"},{"doi-asserted-by":"publisher","key":"e_1_2_7_6_1","DOI":"10.2337\/dc09-S013"},{"doi-asserted-by":"publisher","key":"e_1_2_7_7_1","DOI":"10.2337\/dc08-9025"},{"doi-asserted-by":"publisher","key":"e_1_2_7_8_1","DOI":"10.4158\/EP.15.6.540"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"UK Prospective Diabetes Study 16: overview of 6\u2009years' therapy of type II diabetes: a progressive disease","volume":"44","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1995","journal-title":"Diabetes"},{"doi-asserted-by":"publisher","key":"e_1_2_7_10_1","DOI":"10.1007\/s00125-012-2534-0"},{"doi-asserted-by":"publisher","key":"e_1_2_7_11_1","DOI":"10.7326\/0003-4819-156-3-201202070-00011"},{"doi-asserted-by":"publisher","key":"e_1_2_7_12_1","DOI":"10.1007\/s11095-012-0739-z"},{"doi-asserted-by":"publisher","key":"e_1_2_7_13_1","DOI":"10.1016\/S0140-6736(12)60205-0"},{"doi-asserted-by":"publisher","key":"e_1_2_7_14_1","DOI":"10.1016\/S0140-6736(12)60204-9"},{"issue":"1","key":"e_1_2_7_15_1","first-page":"S53","article-title":"Insulin degludec does not compromise efficacy or safety when given in a flexible once\u2010daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes","volume":"54","author":"Atkin SL","year":"2011","journal-title":"Diabetologia"},{"issue":"1","key":"e_1_2_7_16_1","first-page":"S423","article-title":"Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes","volume":"54","author":"Birkeland KI","year":"2011","journal-title":"Diabetologia"},{"unstructured":"International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1) Step 4. 10\u20106\u20101996.","key":"e_1_2_7_17_1"},{"unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects\u2014Last amended by the 59th WMA General Assembly Seoul. 2008.","key":"e_1_2_7_18_1"},{"doi-asserted-by":"publisher","key":"e_1_2_7_19_1","DOI":"10.1111\/j.1464-5491.2012.03605.x"},{"issue":"1","key":"e_1_2_7_20_1","first-page":"LB7","article-title":"GAPP2\u2122: global survey finds in the last month one in four type 2 diabetes patients do not take basal insulin as prescribed and over a third suffer hypoglycaemia","volume":"61","author":"Brod M","year":"2012","journal-title":"Diabetes"},{"doi-asserted-by":"publisher","key":"e_1_2_7_21_1","DOI":"10.1111\/j.1742-1241.2009.02176.x"},{"doi-asserted-by":"publisher","key":"e_1_2_7_22_1","DOI":"10.1016\/S0140-6736(10)62305-7"},{"issue":"1","key":"e_1_2_7_23_1","first-page":"A269","article-title":"The effect of insulin degludec on glycemic control and nocturnal hypoglycemia compared with insulin glargine: a 1\u2010year randomized trial in insulin\u2010na\u00efve people with type 2 diabetes","volume":"61","author":"Zinman B","year":"2012","journal-title":"Diabetes"},{"issue":"1","key":"e_1_2_7_24_1","first-page":"A272","article-title":"Insulin degludec improves glycemic control in insulin\u2010na\u00efve patients with type 2 diabetes: results of a randomized Pan\u2010Asian trial","volume":"61","author":"Onishi Y","year":"2012","journal-title":"Diabetes"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/DMSO.S7327","article-title":"Use of DPP\u20104 inhibitors in type 2 diabetes: focus on sitagliptin","volume":"3","author":"Ahren B","year":"2010","journal-title":"Diabetes Metab Syndr Obes"},{"doi-asserted-by":"publisher","key":"e_1_2_7_26_1","DOI":"10.1111\/j.1463-1326.2012.01606.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12115","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12115","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12115","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:14:00Z","timestamp":1761891240000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,6]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/dom.12115"],"URL":"https:\/\/doi.org\/10.1111\/dom.12115","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2013,5,6]]}}}